| Trial ID: | L3345 |
| Source ID: | NCT01044017
|
| Associated Drug: |
Placebo
|
| Title: |
A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: Placebo|DRUG: RO4998452
|
| Outcome Measures: |
Primary: Effect on postprandial plasma glucose concentration, Following meal 13 hours after dosing | Secondary: Mean postprandial daily plasma glucose concentration (3 consecutive meals), 25 hours|Mean daily blood glucose concentration, pre-meal plasma glucose concentration, plasma insulin concentration, Assessments up to 25 hours after dosing|Urinary glucose excretion, Assessments up to 25 hours after dosing|Safety and tolerability: AEs, laboratory parameters, AEs throughout study, laboratory assessments on 3 treatment days and on follow-up
|
| Sponsor/Collaborators: |
Sponsor: Hoffmann-La Roche
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
22
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2009-12
|
| Completion Date: |
2010-08
|
| Results First Posted: |
|
| Last Update Posted: |
2016-11-02
|
| Locations: |
Strasbourg, 67064, France
|
| URL: |
https://clinicaltrials.gov/show/NCT01044017
|
